— Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility
July 10, 2026
• 2 min read
The FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) in combination with enfortumab vedotin (Padcev) as perioperative treatment for adults with muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility.
This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
